All sponsors

Revolution Medicines, Inc. $RVMD

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-37
RECRUITING11
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%

Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +16.6 months). See all sponsors →

Open Revolution Medicines, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
RASolute 302
NCT06625320
P3Active, not recruitingPancreatic Cancer; PDAC5002026-06
RMC-6236
NCT05379985
P1/2RecruitingNon-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC)7542027-05-31 (+36 mo)
RMC-6291
NCT06162221
P1/2RecruitingNon-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC6162027-06
RASolve 301
NCT06881784
P3RecruitingNSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer5902027-12-01
RASolute 303
NCT07491445
P3RecruitingPancreatic Cancer; Pancreatic Cancer Metastatic9002028-06
RMC-6236
NCT06445062
P1/2RecruitingColorectal Cancer; CRC11302028-09-30 (+17 mo)
Elironrasib
NCT06128551
P1/2RecruitingNon-Small Cell Lung Cancer (NSCLC); Colorectal Cancer5342028-12 (+24 mo)
RASolute 305
NCT07621718
P3RecruitingPancreatic Cancer; Pancreatic Cancer Metastatic6702028-12-30
RASolute 309
NCT07805954
P3RecruitingPancreatic Cancer; Pancreatic Cancer Metastatic4002029-03
Daraxonrasib
NCT07397338
P1/2RecruitingAdvanced Solid Tumors; Metastatic Solid Tumors3702029-05
RASolute 304
NCT07252232
P3RecruitingPancreatic Cancer; PDAC5002029-05-10
RASolve 308
NCT07777822
P3RecruitingNSCLC; Non-small Cell Lung Cancer4302029-10